Wolfgang Miesbach, MD, PhD, on Future Research with EtranaDez

Video

The professor and head of coagulation disorders and Comprehensive Care Centre, University Hospital of Frankfurt, Germany, discussed future integration of EtranaDez into hemophilia B treatment.

“In the future, I think hemophilia centers should be able to offer gene therapy after it has been approved. And one possibility, for example, would be to initiate a hub and spoke model in which there would be a close cooperation between experienced and non-experienced centers to enable patients to be treated with gene therapy.”

The phase 3 HOPE-B study (NCT03569891) met its primary endpoint, with etranacogene dezaparvovec (EtranaDez, AMT-061; CSL Behring, UniQure) significantly reducing annualized bleeding rate (ABR) and demonstrating superiority to Factor IX (FIX) prophylactic therapy. The therapy demonstrated efficacy in patients both with and without neutralizing adeno-associated virus vector antibodies.

The final analysis of HOPE-B were presented by investigator Wolfgang Miesbach, MD, PhD, at the European Association of Haemophilia and Allied Disorders (EAHAD) 2022 Annual Meeting, February 2-4, 2022. Miesbach serves as professor and head of coagulation disorders at the Comprehensive Care Centre at University Hospital of Frankfurt, Germany.

Miesbach and colleagues found that adjusted ABR was reduced by 64% (= .0002) and FIX-treated bleeds reduced by 77% (<.0001) after a 6-month lead-in period over months 7 to 18. Almost all participants (98%) treated with the full dose of EtranaDez were able to discontinue prophylaxis.

CGTLive spoke with Miesbach to learn more about research that remains to be conducted with EtranaDez. He discussed potential ways the therapy could be integrated into treatment for patients with hemophilia B.

REFERENCE
Final analysis of pivotal HOPE-B study demonstrates durable and sustained therapeutic effect of etranacogenedezaparvovec gene therapy in hemophilia B – Data presented at EAHAD 2022. News release. CSL Behring. February 4, 2022. https://www.cslbehring.com/newsroom/2022/hope-b-data-presented-at-eahad2022

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.